Abstract
Erb-B-3 overexpression is associated with poor prognosis in non-small cell lung cancer and is often overexpressed in breast cancers. MMTVhuman-erb-B-3 transgenic mice were generated to evaluate the impact of erb-B-3 overexpression on lung and mammary gland tumorigenesis. These transgenic mice developed a high incidence of lung adenocarcinomas but not mammary gland tumors. The tumors overexpressed transgenic human [h]-erb-B-3 but also overexpressed endogenous erb-B-2, indicating that the heterodimer of h-erb-B-3-erb-B-2 was required for proliferative signal transduction to the nucleus. Lung tumor latency was shorter and the incidence higher in erb-B-3 transgenic mice treated with the methylating agent, methylnitrosourea [MNU]. In MNU treated mice, K-ras activating point mutations in codon 12, synergized with h-erb-B-3 in lung tumorogenesis. In bitransgenic MMTVrat-erb-B2/MMTV-human-erb-B-3 mice, lung tumor latency was also significantly shortened. Unlike over-expression of rat-erb-B-2, overexpression of h-erb-B-3 did not alter the incidence or latency of mammary tumors. Coupled erb-B-2 and erb-B-3 overexpression as well as K-ras activation induced signaling through mitogen-activated protein kinase (MAPK). This animal model links erb-B-3 with lung cancer, suggests that erb-B-2 and erb-B-3 heterodimerization is a necessary intermediate, and documents latency shortening by methylating agent-induced mutation of K-ras. This erb-B-3 mouse lung cancer model will help dissect genetic changes in lung tumorigenesis and may be useful for chemoprevention studies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adamson ED, Wiley LM . 1997 Curr. Top. Dev. Biol. 35: 71–120
Ahrendt SA, Decker PA, Alawi E, Zhu Yr Y, Sanchez-Cespedes M, Yang SC, Haasler GB, Kajdacsy-Balla A, Demeure MJ, Sidransky D . 2001 Cancer 92: 1525–1530
al Moustafa AE, Alaoui-Jamali M, Paterson J, O'Connor-McCourt M . 1999 Anticancer Res. 19: 481–486
Carraway III KL, Sliwkowski MX, Akita R, Platko JV, Guy PM, Nuijens A, Diamonti AJ, Vandlen RL, Cantley LC, Cerione RA . 1994 J. Biol. Chem. 269: 14303–14306
Cohen BD, Siegall CB, Bacus S, Foy L, Green JM, Hellstrom I, Hellstrom KE, Fell HP . 1998 Biochem. Soc. Symp. 63: 199–210
Devereux TR, Anderson MW, Belinsky SA . 1991 Carcinogenesis 12: 299–303
Dumenco LL, Allay E, Norton K, Gerson SL . 1993 Science 259: 219–222
Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway III KL . 1994 Proc. Natl. Acad. Sci. USA 91: 8132–8136
Hung MC, Lau YK . 1999 Semin. Oncol. 26: 51–59
Jo SA, Zhu X, Marchionni MA, Burden SJ . 1995 Nature 373: 158–161
Kiguchi K, Bol D, Carbajal S, Beltran L, Moats S, Chan K, Jorcano J, DiGiovanni J . 2000 Oncogene 19: 4243–4254
Kristiansen G, Yu Y, Petersen S, Kaufmann O, Schluns K, Dietel M, Petersen I . 2001 Eur. J. Cancer 37: 1089–1095
Liu L, Qin X, Gerson SL . 1999 Carcinogenesis 20: 279–284
Muller WJ, Arteaga CL, Muthuswamy SK, Siegel PM, Webster MA, Cardiff RD, Meise KS, Li F, Halter SA, Coffey RJ . 1996 Mol. Cell. Biol. 16: 5726–5736
Patel NV, Acarregui MJ, Snyder JM, Klein JM, Sliwkowski MX, Kern JA . 2000 Am. J. Respir. Cell Mol. Biol. 22: 432–440
Peterson LA, Thomson NM, Crankshaw DL, Donaldson EE, Kenney PJ . 2001 Cancer Res. 61: 5757–5763
Plowman GD, Whitney GS, Neubauer MG, Green JM, McDonald VL, Todaro GJ, Shoyab M . 1990 Proc. Natl. Acad. Sci. USA 87: 4905–4909
Polosa R, Prosperini G, Tomaselli V, Howarth PH, Holgate ST, Davies DE . 2000 J. Allergy Clin. Immunol. 106: 1124–1131
Qin X, Liu L, Gerson SL . 1999a Oncogene 18: 4394–4400
Qin X, Zhou H, Liu L, Gerson SL . 1999b Carcinogenesis 20: 1667–1673
Reese JS, Allay E, Gerson SL . 2001 Oncogene 20: 5258–5263
Reinmuth N, Brandt B, Kunze WP, Junker K, Thomas M, Achatzy R, Scheld HH, Semik M . 2000 Eur. Respir. J. 16: 991–996
Schlessinger J . 2000 Cell 103: 211–225
Siegel PM, Dankort DL, Hardy WR, Muller WJ . 1994 Mol. Cell. Biol. 14: 7068–7077
Sundaresan S, Roberts PE, King KL, Sliwkowski MX, Mather JP . 1998 Endocrinology 139: 4756–4764
Weinstein EJ, Leder P . 2000 Cancer Res. 60: 3856–3861
Yi ES, Harclerode D, Gondo M, Stephenson M, Brown RW, Younes M, Cagle PT . 1997 Mod. Pathol. 10: 142–148
Zaidi NH, Pretlow TP, O'Riordan MA, Dumenco LL, Allay E, Gerson SL . 1995 Carcinogenesis 16: 451–456
Zhou H, Chen W-D, Qin X, Lee K, Liu L, Markowitz S, Gerson SL . 2001 Oncogene 42: 6009–6017
Acknowledgements
We thank the Edison Biotechnology Center at Ohio University, Athens, Ohio, for the generation of the human-erb-B-3 transgenic mice and Dr William Muller for the erb-B-2 transgenic mice. This work was supported by Public Health Service Grants RO1CA63193, RO1CA73062, RO1ES06288, and P30CA43703.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhou, H., Liu, L., Lee, K. et al. Lung tumorigenesis associated with erb-B-2 and erb-B-3 overexpression in human erb-B-3 transgenic mice is enhanced by methylnitrosourea. Oncogene 21, 8732–8740 (2002). https://doi.org/10.1038/sj.onc.1205984
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205984
Keywords
This article is cited by
-
GLI pathogenesis-related 1 functions as a tumor-suppressor in lung cancer
Molecular Cancer (2016)
-
Dynamic probabilistic threshold networks to infer signaling pathways from time-course perturbation data
BMC Bioinformatics (2014)
-
The ERBB3 receptor in cancer and cancer gene therapy
Cancer Gene Therapy (2008)
-
Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549
Oncogene (2005)